Form 4 Filing for Niagen Bioscience, Inc.

This filing details a transaction by Pamir Ozan, Chief Financial Officer of Niagen Bioscience, Inc. On June 30, 2026, Ozan acquired 4,255 shares of Common Stock at a price of $2.71 per share through the Issuer's Employee Stock Purchase Plan. This acquisition is exempt under Rule 16b-3(c) and 16b-3(d). Following this transaction, Ozan directly owns 11,627.159 shares. Additionally, 2,220.443 shares are held indirectly by Ozan's spouse. The filing was signed by Jeong James Lee, Attorney-in-Fact, on July 8, 2026.